Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
25
SNTI Quote, Financials, Valuation and Earnings
Last price:
$0.94
Seasonality move
:
-21.45%
Day range:
$0.93 - $0.98
52-week range:
$0.80 - $5.10
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.27x
P/B ratio:
3.08x
Volume:
106K
Avg. volume:
203.1K
1-year change:
-66.93%
Market cap:
$25M
Revenue:
--
EPS (TTM):
-$3.34
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
$500K | -$0.47 | -- | -29.56% | $11.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.85 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
IBIO
iBio, Inc.
|
$33.3K | -$0.07 | -83.34% | -87.42% | $5.60 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
VOR
Vor Biopharma, Inc.
|
-- | -$1.00 | -- | -282.69% | $44.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
$0.95 | $11.50 | $25M | -- | $0.00 | 0% | 3.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.39 | $31.85 | $4B | 10.22x | $0.00 | 0% | 3.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$327.30 | $457.00 | $43.4B | 145.01x | $0.00 | 0% | 11.76x |
|
IBIO
iBio, Inc.
|
$2.83 | $5.60 | $97.8M | -- | $0.00 | 0% | 420.73x |
|
SVRA
Savara, Inc.
|
$5.62 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
VOR
Vor Biopharma, Inc.
|
$15.05 | $44.60 | $103M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
78.76% | -1.416 | 81.25% | 1.03x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
IBIO
iBio, Inc.
|
4.15% | 1.951 | 4.22% | 8.94x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
|
VOR
Vor Biopharma, Inc.
|
-0.14% | 23.817 | 0.92% | 9.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNTI
Senti Biosciences, Inc.
|
-$904K | -$16.9M | -79.41% | -173.17% | -- | -$9.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
IBIO
iBio, Inc.
|
-$241K | -$6.9M | -72.75% | -80.97% | -5951% | -$5.8M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
VOR
Vor Biopharma, Inc.
|
-$2K | -$28.1M | -- | -- | -- | -$53.9M |
Senti Biosciences, Inc. vs. Competitors
-
Which has Higher Returns SNTI or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of 96.33%. Senti Biosciences, Inc.'s return on equity of -173.17% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About SNTI or ACAD?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1107.48%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.85 which suggests that it could grow by 36.17%. Given that Senti Biosciences, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Senti Biosciences, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is SNTI or ACAD More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock SNTI or ACAD?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or ACAD?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Senti Biosciences, Inc.'s net income of -$18.1M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 3.70x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M ACADACADIA Pharmaceuticals, Inc.3.70x 10.22x $284M $273.6M
-
Which has Higher Returns SNTI or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of 16.99%. Senti Biosciences, Inc.'s return on equity of -173.17% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About SNTI or ALNY?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1107.48%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 39.63%. Given that Senti Biosciences, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is SNTI or ALNY More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock SNTI or ALNY?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or ALNY?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Senti Biosciences, Inc.'s net income of -$18.1M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 145.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 11.76x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M ALNYAlnylam Pharmaceuticals, Inc.11.76x 145.01x $1.1B $186.4M
-
Which has Higher Returns SNTI or IBIO?
iBio, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of -5720%. Senti Biosciences, Inc.'s return on equity of -173.17% beat iBio, Inc.'s return on equity of -80.97%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M IBIOiBio, Inc.-189% -$0.09 $59M -
What do Analysts Say About SNTI or IBIO?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1107.48%. On the other hand iBio, Inc. has an analysts' consensus of $5.60 which suggests that it could grow by 97.88%. Given that Senti Biosciences, Inc. has higher upside potential than iBio, Inc., analysts believe Senti Biosciences, Inc. is more attractive than iBio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 IBIOiBio, Inc.6 0 0 -
Is SNTI or IBIO More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison iBio, Inc. has a beta of 1.180, suggesting its more volatile than the S&P 500 by 17.972%.
-
Which is a Better Dividend Stock SNTI or IBIO?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. iBio, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or IBIO?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than iBio, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is lower than iBio, Inc.'s net income of -$9M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while iBio, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus 420.73x for iBio, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M IBIOiBio, Inc.420.73x -- -- -$9M
-
Which has Higher Returns SNTI or SVRA?
Savara, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About SNTI or SVRA?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1107.48%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 92.39%. Given that Senti Biosciences, Inc. has higher upside potential than Savara, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 SVRASavara, Inc.6 0 0 -
Is SNTI or SVRA More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock SNTI or SVRA?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or SVRA?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns SNTI or VOR?
Vor Biopharma, Inc. has a net margin of -- compared to Senti Biosciences, Inc.'s net margin of --. Senti Biosciences, Inc.'s return on equity of -173.17% beat Vor Biopharma, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNTISenti Biosciences, Inc.-- -$0.69 $38.2M VORVor Biopharma, Inc.-- -$121.63 -$2.2B -
What do Analysts Say About SNTI or VOR?
Senti Biosciences, Inc. has a consensus price target of $11.50, signalling upside risk potential of 1107.48%. On the other hand Vor Biopharma, Inc. has an analysts' consensus of $44.60 which suggests that it could grow by 196.35%. Given that Senti Biosciences, Inc. has higher upside potential than Vor Biopharma, Inc., analysts believe Senti Biosciences, Inc. is more attractive than Vor Biopharma, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SNTISenti Biosciences, Inc.3 0 0 VORVor Biopharma, Inc.5 1 0 -
Is SNTI or VOR More Risky?
Senti Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vor Biopharma, Inc. has a beta of 1.989, suggesting its more volatile than the S&P 500 by 98.949%.
-
Which is a Better Dividend Stock SNTI or VOR?
Senti Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vor Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Senti Biosciences, Inc. pays -- of its earnings as a dividend. Vor Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SNTI or VOR?
Senti Biosciences, Inc. quarterly revenues are --, which are smaller than Vor Biopharma, Inc. quarterly revenues of --. Senti Biosciences, Inc.'s net income of -$18.1M is higher than Vor Biopharma, Inc.'s net income of -$812.7M. Notably, Senti Biosciences, Inc.'s price-to-earnings ratio is -- while Vor Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Senti Biosciences, Inc. is 3.27x versus -- for Vor Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNTISenti Biosciences, Inc.3.27x -- -- -$18.1M VORVor Biopharma, Inc.-- -- -- -$812.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
93
NBTX alert for Mar 5
Nanobiotix SA [NBTX] is up 17.92% over the past day.
Sell
45
MRNA alert for Mar 5
Moderna, Inc. [MRNA] is up 16.05% over the past day.
Buy
77
SSRM alert for Mar 5
SSR Mining, Inc. [SSRM] is up 14.97% over the past day.
